Parasitic Infections and Cancer: A Status Report

Abstract

There are many tropical parasitic infections that are still present public health problem in tropical medicine. Of interest, some diseases are proved for the relationship with carcinogenesis. Many cancers are proved for the etiopathogenesis due to parasitic infections. The well-known tropical parasitic infections that can induce carcinogenesis are opisthorchiasis, clonorchiasis, and schistosomiasis. To prevent parasitic infection related cancer is an important consideration in clinical oncology. The standard practice is the prevention of the infection, but the hope is the development of the new vaccines for cancer prevention. Here, the authors briefly review on the current status on the cancer vaccines against the three important tropical diseases that can result in cancers, opisthorchiasis, clonorchiasis, and schistosomiasis.

Keywords

Cancer - clonorchiasis - opisthorchiasis - parasite - schistosomiasis - vaccine

• References

• 1 Vyshenska D, Lam KC, Shulzhenko N, Morgun A. Interplay between viruses and bacterial microbiota in cancer development. Semin Immunol 2017; 32: 14-24
• 2 Viarisio D, Gissmann L, Tommasino M. Human papillomaviruses and carcinogenesis: Well-established and novel models. Curr Opin Virol 2017; 26: 56-62
• 3 van Tong H, Brindley PJ, Meyer CG, Velavan TP. Parasite infection, carcinogenesis and human malignancy. EBioMedicine 2017; 15: 12-23
• 4 Machicado C, Marcos LA. Carcinogenesis associated with parasites other than Schistosoma, Opisthorchis and Clonorchis: A systematic review. Int J Cancer 2016; 138: 2915-21
• 5 Prueksapanich P, Piyachaturawat P, Aumpansub P, Ridtitid W, Chaiteerakij R, Rerknimitr R. et al. Liver fluke-associated biliary tract cancer. Gut Liver. 2017. Doi: 10.5009/gnl17102. [Epub ahead of print]
• 6 Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Natl Canc Inst 2012; 24: 151-9
• 7 Sripa B, Echaubard P. Prospects and challenges towards sustainable liver fluke control. Trends Parasitol 2017; 33: 799-812
• 8 Wiwanitkit V. Clinical findings among 62 Thais with cholangiocarcinoma. Trop Med Int Health 2003; 8: 228-30
• 9 Chai JY, Darwin Murrell K, Lymbery AJ. Fish-borne parasitic zoonoses: Status and issues. Int J Parasitol 2005; 35: 1233-54
• 10 Buisson Y. Control of Opisthorchis viverrini infection for cholangiocarcinoma prevention. Bull Soc Pathol Exot 2017; 110: 61-7
• 11 Wiwanitkit V. Finding for epitope within egg shell protein of human liver fluke: A clue for cholangiocarcinoma vaccine development. South Asian J Cancer 2014; 3: 142-3
• 12 Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M. et al. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. J Hepatol 2016; 65: 849-55
• 13 Kim TS, Pak JH, Kim JB, Bahk YY. Clonorchis sinensis, an oriental liver fluke, as a human biological agent of cholangiocarcinoma: A brief review. BMB Rep 2016; 49: 590-7
• 14 Tang ZL, Huang Y, Yu XB. Current status and perspectives of Clonorchis sinensis and clonorchiasis: Epidemiology, pathogenesis, omics, prevention and control. Infect Dis Poverty 2016; 5: 71
• 15 Chung EJ, Jeong YI, Lee MR, Kim YJ, Lee SE, Cho SH. et al. Heat shock proteins 70 and 90 from Clonorchis sinensis induce Th1 response and stimulate antibody production. Parasit Vectors 2017; 10: 118
• 16 Wu Z, Tang Z, Shang M, Zhao L, Zhou L, Kong X. et al. Comparative analysis of immune effects in mice model: Clonorchis sinensis cysteine protease generated from recombinant Escherichia coli and Bacillus subtilis spores. Parasitol Res 2017; 116: 1811-22
• 17 Wiwanitkit V. Overview of clinical reports on urinary schistosomiasis in the tropical Asia. Pak J Med Sci 2005; 21: 499-501
• 18 Egesa M, Hoffmann KF, Hokke CH, Yazdanbakhsh M, Cose S. Rethinking schistosomiasis vaccine development: Synthetic vesicles. Trends Parasitol 2017; 33: 918-21
• 19 Hsieh MH, Brotherton JM, Siddiqui AA. Hepatitis B vaccines and HPV vaccines have been hailed as major public health achievements in preventing cancer – Could a schistosomiasis vaccine be the third?. PLoS Negl Trop Dis 2015; 9: e0003598
• 20 Carvalho GB, Pacífico LG, Pimenta DL, Siqueira LM, Teixeira-Carvalho A, Coelho PM. et al. Evaluation of the use of C-terminal part of the Schistosoma mansoni 200kDa tegumental protein in schistosomiasis diagnosis and vaccine formulation. Exp Parasitol 2014; 139: 24-32
• 21 Tallima H, Dvořák J, Kareem S, Abou El Dahab M, Abdel Aziz N, Dalton JP. et al. Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase. PLoS Negl Trop Dis 2017; 11: e0005443
• 22 Siddiqui AA, Siddiqui SZ. Sm-p80-based schistosomiasis vaccine: Preparation for human clinical trials. Trends Parasitol 2017; 33: 194-201